Enfermedad mínima residual en cánceres colorrectales de alto riesgo resecados. Valor de las biopsias líquidas en el seguimiento y análisis de la heterogeneidad tumoral.

Datos básicos

Protocolo:
PI15/02180
EUDRACT:
NCT:
Centro:
Año de incio:
2016
Año de finalización:
2019
PROYECTO DE INVESTIGACIÓN NACIONAL F.COMPETITIVA FIN. PUBLICA 80.465,00 €

Documentos

  • No hay documentos

Participantes

Grupos y Plataformas de I+D+i

Financiadores - Promotores

INSTITUTO SALUD CARLOS III

Resultados del Ensayo Clínico


Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer.

Smyth, Elizabeth C, Cervantes, Andres

Editorial Material. 10.1136/esmoopen-2020-001107. 2020


Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes

Ragulan, C; (...); Sadanandam, A

Article. 10.1038/s41598-019-43492-0. 2019


Definition of the Rectum: An International, Expert-based Delphi Consensus.

D'Souza N; (...); Brown G

Article. 10.1097/SLA.0000000000003251. 2019


Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.

Tarazona, Noelia; (...); Cervantes, Andres

Article. 10.1136/esmoopen-2020-000847. 2020


EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness.

Gimeno-Valiente, F; (...); Castillo, J

Article. 10.1038/s41598-020-60476-7. 2020


Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer.

Gimeno-Valiente, F; (...); Castillo, J

Article. 10.3390/cancers13061433. 2021


Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen.

Martinez-Ciarpaglini, Carolina; (...); Cervantes, Andres

Article. 10.1111/his.13900. 2019


In the literature: December 2019

Gambardella, V; (...); Cervantes, A

Editorial Material. 10.1136/esmoopen-2019-000642. 2020


In the literature: February 2020

Roda, D; (...); Cervantes, A

Editorial Material. 10.1136/esmoopen-2020-000680. 2020


In the literature: October 2019

Editorial Material. 10.1136/esmoopen-2019-000613. 2019

  • Open Access.

Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression

Martinez-Ciarpaglini, C; (...); Cervantes, A

Article. 10.1038/s41379-018-0124-5. 2019


Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.

Papaccio, Federica; (...); Cervantes, Andres

Article. 10.3390/cancers12123611. 2020


Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress.

Gambardella, Valentina; (...); Cervantes, Andres

Article. 10.3390/jcm9093049. 2020


Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by PK Garg, R. Kumar and P. Dixit

Smyth, E C; (...); Fleitas, T

Letter. 10.1016/j.annonc.2021.05.795. 2021


Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer

Tarazona, N; (...); Cervantes, A

Article. 10.1093/annonc/mdz390. 2019

  • Open Access.

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.

Gambardella, V; (...); Fleitas, T

Article. 10.1016/j.ctrv.2020.102015. 2020


Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma.

Gambardella, V; (...); Cervantes, A

Review. 10.1093/annonc/mdz143. 2019


Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations.

Roda, D, Rosello, S, Cervantes, A

Editorial Material. 10.1093/annonc/mdz229. 2019


ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer.

Gimeno-Valiente F; (...); López-Rodas G

Article. 10.1038/s41598-019-45411-9. 2019


Compartir